First Light Acquisition in a press release said today’s shareholder meeting to vote on the proposed merger with Calidi Biotherapeutics has been adjourned until Aug. 28 at 10:30 a.m. Eastern. The meeting was previously scheduled for Aug. 22 and postponed until today.
The target is focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs.
As announced in January, the deal has a pro forma enterprise valuation of approximately $335 million.
This is Calidi’s second attempt to go public via a SPAC transaction. Edoc Acquisition called off its plan of merger with Calidi a year ago. Edoc in May 2022 had lowered the aggregate value of the consideration to Calidi from $400 million to $380 million. Read more.
